Declan McGuone, FRCPath Neuro, MBBCh
Associate Professor of PathologyCards
About
Research
Publications
2025
Abusive Head Trauma in Infants and Children: Technical Report.
Narang S, Haney S, Duhaime A, Martin J, Binenbaum G, de Alba Campomanes A, Barth R, Bertocci G, Care M, McGuone D, Laskey A, Asnes A, Brown V, Girardet R, Heavilin N, Kissoon N, McGregory K, Morgan P, Rosado N, Flaherty E, Sirotnak A, Haney S, Gavril A, Hoffert Gilmartin A, Idzerda S, Messner S, Legano L, Mohr B, Moles R, Palusci V, Nienow S, Budzak A, Suh D, Yoo S, Dumitrescu A, Fredrick D, Gise R, Strominger M, Rubin S, Karr D, Nischal K, Roarty J, Otero H, Milla S, Mercado-Deane M, Alazraki A, Annam A, Benya E, Acharya P, Brown B, Barton K, Daugherty R, Albert G, Bauer D, Ducis K, Lam S, Martin J, Rocque B, Aldana P, Brockmeyer D, Duhaime A, Jea A, Otero H, Milla S, Mercado-Deane M, Alazraki A, Annam A, Benya E, Acharya P, Brown B, Barton K, Daugherty R, Albert G, Bauer D, Ducis K, Lam S, Martin J, Rocque B, Aldana P, Brockmeyer D, Duhaime A, Jea A. Abusive Head Trauma in Infants and Children: Technical Report. Pediatrics 2025, 155 PMID: 39992695, DOI: 10.1542/peds.2024-070457.Peer-Reviewed Original ResearchExploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury
Wachtler N, O’Brien R, Ehrlich B, McGuone D. Exploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury. Pharmaceuticals 2025, 18: 223. PMID: 40006037, PMCID: PMC11859800, DOI: 10.3390/ph18020223.Peer-Reviewed Original ResearchCalcium signalingCalcium channelsTherapeutic strategiesCalcium homeostasisFunction of calcium channelsDysregulated calcium signalingModulation of injuryTraumatic brain injuryBrain injuryLoss of calcium homeostasisBlast-related traumatic brain injuryDevelopment of neuroprotective interventionsIntracellular calcium dynamicsPlasma membrane stabilityExtracellular calciumBlast traumatic brain injuryPreclinical modelsTherapeutic outcomesNeuroprotective interventionsMembrane abnormalitiesPharmacological inhibitorsNeuronal somataExclusion criteriaCalcium dynamicsSecondary injury
2024
EPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS
Alanya H, Yalcin K, Hilton B, Gultekin B, Mishra-Gorur K, McGuone D, Gunel M, Omay S, Erson-Omay Z. EPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS. Neuro-Oncology 2024, 26: viii9-viii9. PMCID: PMC11553213, DOI: 10.1093/neuonc/noae165.0034.Peer-Reviewed Original ResearchGH-secreting pituitary adenomasWhole-exome sequencingPituitary adenomasGNAS mutationsCopy number variationsSporadic GH-secreting pituitary adenomasGrowth hormone (GH)-secreting pituitary adenomasGenomic profilingGrowth hormone secreting pituitary adenomaSecreting pituitary adenomasBlood samplesComprehensive genomic characterizationSomatic GNAS mutationsSingle nucleotide variantsMatched blood samplesGenomic instabilityAssessment of genomic instabilityStatistically significant differenceTumor sizeClinical featuresTumor samplesClinical dataTumorExome sequencingBrain tumorsRocky Mountain Spotted Fever Encephalitis and “Starry Sky” Pattern on MRI
Mikhaiel J, Parasram M, Park J, Cappucci S, McGuone D, Falcone G, Sheth K, Gilmore E. Rocky Mountain Spotted Fever Encephalitis and “Starry Sky” Pattern on MRI. The Neurologist 2024, 30: 34-38. PMID: 39382206, DOI: 10.1097/nrl.0000000000000586.Peer-Reviewed Original ResearchMagnetic resonance imagingPetechial rashCase reportDiffusion restrictionMagnetic resonance imaging brainMagnetic resonance imaging brain findingsRepeat MRI brainRocky Mountain spotted feverUrinary tract infectionFoci of diffusion restrictionRight centrum semiovaleProgression to comaPerivascular lymphocytic infiltrateDiffuse petechial rashTract infectionsClinical presentationViral cultureClinical improvementMRI brainLymphocytic infiltrationLumbar punctureSkin biopsiesElevated proteinNeurological manifestationsPunctate fociBSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE
Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.Peer-Reviewed Original ResearchNon-small cell lung cancerLeptomeningeal diseaseCentral nervous systemLeptomeningeal metastasesParenchymal metastasesCerebrospinal fluidTumor cellsTyrosine kinase inhibitor treatmentCell lung cancerKinase inhibitor treatmentCerebrospinal fluid of patientsCell linesCerebral lateral ventriclesIntra-arterial injectionTGF-b signalingIn vivo passageIntraparenchymal diseaseMechanisms of progressionTumor microenvironmentMultiplex immunofluorescenceAggressive treatmentLeptomeningeal infiltrationPerivascular invasionIntraparenchymal metastasesMurine modelHeterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas
Tabor J, O'Brien J, Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas. Neurosurgery 2024, 70: 203-203. DOI: 10.1227/neu.0000000000002810_112.Peer-Reviewed Original ResearchProgression-free survivalHigh-grade meningiomasOverall survivalNF2 mutationsDecreased PFSLow grade meningiomasWHO grading criteriaLow-grade meningiomasAssociated with recurrenceSomatic NF2 mutationsHigher recurrence rateSomatic driver mutationsAggressive clinical characteristicsIncreased chromosomal instabilityLoss of CDKN2A/BHigh-copy number variationCDKN2A mutationsCopy number variationsAggressive meningiomasLow-grade onesProliferative indexCDKN2A lossGrade meningiomasRecurrence rateMitotic countVariations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.
Tabor J, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal M, Yalcin K, Morales-Valero S, Marianayagam N, Alanya H, Elsamadicy A, Millares Chavez M, Aguilera S, Mishra-Gorur K, McGuone D, Fulbright R, Jin L, Erson-Omay E, Günel M, Moliterno J. Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group. Journal Of Neurosurgery 2024, 141: 664-672. PMID: 38518289, DOI: 10.3171/2024.1.jns231633.Peer-Reviewed Original ResearchBlack patientsSporadic meningiomasClinical outcomesGenomic profilingClinical behavior of meningiomasShorter progression-free survivalAnterior skull base tumorsClinical data of patientsHispanic patientsProgression-free survivalChromosome 1p deletionBehavior of meningiomasIncreased recurrence rateRate of recurrenceSkull base tumorsData of patientsSomatic driver mutationsNon-Black patientsShorter PFSOverall survivalAggressive meningiomasTRAF7 mutationsIntracranial meningiomasMeningioma resectionNon-black groupRaphe and ventrolateral medulla proteomics in sudden unexplained death in childhood with febrile seizure history
Leitner D, William C, Faustin A, Kanshin E, Snuderl M, McGuone D, Wisniewski T, Ueberheide B, Gould L, Devinsky O. Raphe and ventrolateral medulla proteomics in sudden unexplained death in childhood with febrile seizure history. Acta Neuropathologica 2024, 148: 76. PMID: 39607506, PMCID: PMC11604820, DOI: 10.1007/s00401-024-02832-9.Peer-Reviewed Original ResearchConceptsMedullary rapheSudden infant death syndromeVentrolateral medullaFebrile seizuresSudden unexplained deathWeighted gene correlation network analysisDorsal rapheUnexplained deathMidbrain dorsal rapheSUDC casesSignaling pathwayEukaryotic translation initiationGene Ontology biological processesSynaptic vesicle cycleLabel-free quantitative mass spectrometryEukaryotic translation elongationSudden unexpected deathGene correlation network analysisDifferential expression analysisDecreased cellular respirationFebrile seizure historyQuantitative mass spectrometryAutonomic dysfunctionCorrelation network analysisCoagulation system
2023
Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury
Kapate N, Liao R, Sodemann R, Stinson T, Prakash S, Kumbhojkar N, Suja V, Wang L, Flanz M, Rajeev R, Villafuerte D, Shaha S, Janes M, Park K, Dunne M, Golemb B, Hone A, Adebowale K, Clegg J, Slate A, McGuone D, Costine-Bartell B, Mitragotri S. Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury. PNAS Nexus 2023, 3: pgad434. PMID: 38187808, PMCID: PMC10768983, DOI: 10.1093/pnasnexus/pgad434.Peer-Reviewed Original ResearchTraumatic brain injuryBrain injuryAnti-inflammatory interleukin-4Cortical impact (CCI) TBI modelCell therapyAcute clinical managementDysregulated inflammatory responseSecondary brain injuryAnti-inflammatory phenotypeBrain lesion siteImmune cell therapyRole of macrophagesLarge animal modelUnique therapeutic potentialWound-healing phenotypeRampant inflammationProinflammatory biomarkersTBI modelImmunomodulatory effectsInflammation modulationCurrent therapiesMacrophage-based therapiesNeuroprotection mechanismsProinflammatory activationSerum concentrationsEPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS
Tabor J, Chavez M, O'Brien J, Morales-Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. EPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS. Neuro-Oncology 2023, 25: v134-v135. PMCID: PMC10639255, DOI: 10.1093/neuonc/noad179.0509.Peer-Reviewed Original ResearchProgression-free survivalShorter progression-free survivalHigh recurrence rateHigh-grade meningiomasCDKN2A/BOverall survivalRecurrence rateLow-grade meningiomasHeterozygous lossNF2 mutationsHigh mitotic countFree survivalMethods ClinicalSomatic NF2 mutationsClinical associationsLower OSHigh recurrenceLow-grade onesProliferative indexMitotic countAggressive meningiomasClinical implicationsMeningiomasPotential associationSkull base
Clinical Care
Overview
Declan McGuone, MBBCh (a medical degree awarded outside the U.S.), is a neuropathologist who focuses on diagnosing diseases of the brain and nervous system. He also provides autopsy pathology to help determine causes of death and anatomic pathology to examine how disease affects tissues.
As an associate professor of pathology at Yale School of Medicine, Dr. McGuone investigates how certain tumors and injuries develop in the nervous system, with the aim of improving patient care.
He received his medical training from the Royal College of Surgeons in Ireland, completed a residency in anatomic pathology at Massachusetts General Hospital, and pursued fellowships in forensic pathology at the New York City Office of the Chief Medical Examiner and neuropathology at Massachusetts General Hospital.
Clinical Specialties
Anatomic Pathology; Autopsy Pathology; Neuropathology
News
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
310 Cedar Street BML254-C
New Haven, CT 06510
United States
Administrative Support
Events
Apr 202530Wednesday
- Yale OnlyDeclan McGuone, FRCPath Neuro, MBBCh